GRAL - NASDAQ
GRAIL, Inc.
$61.13
-5.1%GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
At a Glance
Live SnapshotGRAIL, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
GRAIL, Inc. Balance Sheet
GRAL • NASDAQ
| GRAIL, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
249.7M | 214.2M | 97.3M | 241.6M | 221.2M | 170.2M | 143.2M | 95.1M | |
654.7M | 549.2M | 0.0 | 0.0 | 0.0 | 413.3M | 401.2M | 546.3M | |
904.4M | 763.5M | 97.3M | 241.6M | 221.2M | 583.5M | 544.3M | 641.4M | |
18.3M | 24.6M | 22.4M | 18.6M | 6.9M | 0.0 | 0.0 | 0.0 | |
18.3M | 20.3M | 16.9M | 15.6M | 6.9M | 0.0 | 0.0 | 0.0 | |
0.0 | 4.3M | 5.4M | 3.1M | 0.0 | 0.0 | 0.0 | 0.0 | |
16M | 18.6M | 21.7M | 19.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 13.1M | 14.7M | 15.7M | 7.8M | 12.4M | 13.2M | 7.9M | |
15.1M | 0.0 | 0.0 | 0.0 | 6.9M | 0.0 | 0.0 | 0.0 | |
953.8M | 819.9M | 156.1M | 295.6M | 242.7M | 595.9M | 557.5M | 649.2M | |
NON-CURRENT ASSETS | ||||||||
103.9M | 135.4M | 169.4M | 198.7M | 216.4M | 101.4M | 59.5M | 33M | |
0.0 | 0.0 | 888.9M | 1.5B | 6.2B | 0.0 | 0.0 | 0.0 | |
1.9B | 2B | 2.7B | 2.9B | 3.1B | 0.0 | 0.0 | 0.0 | |
1.9B | 2B | 3.6B | 4.4B | 9.3B | 0.0 | 0.0 | 0.0 | |
7M | 0.0 | 4.2M | 4.5M | 0.0 | 2.1M | 15.2M | 1.6M | |
0.0 | 0.0 | 643.1M | 664.1M | 0.0 | 0.0 | 0.0 | 0.0 | |
6.8M | 11.1M | 8M | 6.1M | 7.1M | 6.9M | 3.4M | 2.9M | |
2B | 2.2B | 4.4B | 5.3B | 9.5B | 110.4M | 78M | 37.6M | |
2.9B | 3B | 4.6B | 5.6B | 9.7B | 706.3M | 635.5M | 686.8M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
2.1M | 4.8M | 19.7M | 17.5M | 17.6M | 24.5M | 6.1M | 12.8M | |
2.1M | 4.8M | 19.7M | 17.5M | 17.6M | 24.5M | 6.1M | 12.8M | |
0.0 | 34.5M | 41.5M | 38.2M | 61.9M | 41.6M | 33.4M | 59.4M | |
11.7M | 0.0 | 14.8M | 13.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 13.3M | 0.0 | 0.0 | 13.8M | 5.4M | 5.4M | 1.7M | |
0.0 | 1.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
65.9M | 22.7M | 87.6M | 66M | 4.5M | 12.4M | 23K | 267K | |
79.7M | 76.9M | 163.6M | 134.9M | 97.9M | 84M | 44.9M | 74.2M | |
NON-CURRENT LIABILITIES | ||||||||
43.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
218.6M | 345.9M | 676M | 735.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
-40.4M | 2.2M | 1.5M | 3.1M | 112.8M | 3M | 3.4M | 11.5M | |
264.5M | 403M | 747.1M | 821M | 209.5M | 60.5M | 40.1M | 12.3M | |
43.1M | 68.1M | 69.6M | 82.7M | 110.6M | 63M | 36.6M | 800K | |
344.2M | 479.9M | 910.7M | 955.9M | 307.4M | 144.5M | 85M | 86.5M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2B | 1.8B | 1.6B | |
40K | 34K | 11.4B | 11B | 10.3B | 151K | 138K | 129K | |
12.8B | 12.3B | 0.0 | 0.0 | 0.0 | 181M | 90.5M | 57.7M | |
-10.2B | -9.8B | -7.8B | -6.3B | -911.5M | -1.6B | -1.3B | -1.1B | |
2.7M | 1.5M | 1.1M | 894K | 315K | 3.6M | 2.5M | 128K | |
2.6B | 2.5B | 3.6B | 4.6B | 9.4B | 561.8M | 550.5M | 600.4M | |
2.6B | 2.5B | 3.6B | 4.6B | 9.4B | 561.8M | 550.5M | 600.4M | |
SUMMARY | ||||||||
2.9B | 3B | 4.6B | 5.6B | 9.7B | 706.3M | 635.5M | 686.8M | |
661.7M | 549.2M | 4.2M | 4.5M | 0.0 | 415.3M | 415.1M | 546.3M | |
98M | 68.1M | 84.4M | 96M | 110.6M | 63M | 42M | 2.5M | |
-151.7M | -146.1M | -12.9M | -145.6M | -110.6M | -107.2M | -101.1M | -92.6M | |
34,967,211 | 34,967,211 | 34,967,211 | 34,967,211 | 34,967,211 | 34,967,211 | 34,967,211 | 34,967,211 |
SEC Filings
GRAL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your GRAL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.